Larijani, Banafshé http://orcid.org/0000-0003-4735-1169
Miles, James
Ward, Stephen G.
Parker, Peter J.
Article History
Received: 4 November 2020
Revised: 28 December 2020
Accepted: 26 January 2021
First Online: 15 March 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: The original data are with Cancer Research where the article is published.
: B.L. reports a patent for international (PCT) patent application no. PCT/EP2018/062719 “Kits, methods, and their uses for detecting cell–cell interactions”. B.L. also reports the patent PCT/GB14/050715 “TSA amplification in FRET/FLIM”. As disclosed upon submission of the article for peer review, B.L. is a co-founder of FASTBASE Solutions. The competing interests are related to the interpretation of the clinical data. They have been and will be managed in the following manner: The iFRET platform was developed so that it could provide unbiased acquisition and interpretation of data. Hence, it was automated in a specific manner that the operator would not be making biased decisions. Moreover, all the patient samples are blinded during both acquisitions and interpretation of data. The parameters were revealed to us once we had completed the acquisition and interpretation of the data. P.J.P. reports being a co-founder and shareholder of FASTBASE Solutions S.L. outside the submitted work and has a patent for amplified FRET issued and licensed to FASTBASE Solutions and a patent for iFRET pending (FASTBASE license). The other authors declare no competing interests.
: The original research was supported, in part, by Department of Education, Basque Government- IT1270-19, Elkartek grant (BG18) and the Spanish Ministry grant (MINECO) PROJECTS of EXCELLENCE (BFU2015-65625-P). P.J.P. was supported by a core grant to the Francis Crick Institute, from Cancer Research UK (FC001130), the UK Medical Research Council (FC001130) and the Wellcome Trust (FC001130).